Business
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany BERKELEY, Calif. and MAINZ, Germany, May 03, 2023 (GLOBE NEWSWIRE) -- Mainz
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany BERKELEY, Calif. and MAINZ, Germany, May 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has added Eurofins GeLaMed to its network of lab partners offering PCR test kit processing of ColoAlert®, its flagship product that is a highly efficacious and easy to use at-home screening test for colorectal cancer (CRC). Eurofins GeLaMed has four locations throughout Germany and is part of Eurofins Scientific, an international laboratory group with more than 61,000 employees in 61 countries, conducting more than 450 million tests annually. Eurofins GeLaMed provides its customers with a wide range of high-quality services across eleven medical departments covering advanced and modern diagnostic options in human genetics, medical microbiology, laboratory medicine and molecular diagnostics. According to GeLaMed, its almost 500 employees process more than 15,000 orders per working day and offer more than 2,000 different analytical methods from their laboratory medicine and microbiology portfolios under the direction of medical specialists. Marcus Cholewa, Business Line Director Clinical Diagnostics DACH at Eurofins, expressed excitement about the collaboration between Mainz Biomed and Eurofins GeLaMed, stating that Eurofins is always dedicated to delivering excellent customer service, quality, and advanced analytical solutions, as well as the most comprehensive range of testing methods. He also mentioned that Eurofins has a history of introducing innovative and high-value diagnostic testing products, and that by collaborating, they could assist in identifying colorectal cancer (CRC) and provide patients with personalized information to effectively manage their health. Under the terms of the agreement, Eurofins GeLaMed will offer ColoAlert at its testing sites and Mainz Biomed will assist with physician and patient education programs as part of the product launch, highlighting the importance of early screening for the detection and prevention of CRC. About ColoAlertColoAlert®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening k...